Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Risperdal Consta Versus Oral Antipsychotic Medication on Clinical and Functional Outcome and Neurocognition in First-episode Schizophrenia

NCT00330551 is registered in ClinicalTrials.gov with University of California, Los Angeles as lead sponsor.

NCT NCT00330551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00330551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Risperdal Consta Versus Oral Antipsychotic Medication on Clinical and Functional Outcome and Neurocognition in First-episode Schizophrenia
Lead sponsor
University of California, Los Angeles
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2006
Completion date
November 30, 2012
Enrollment
126 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia